Brokerages Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Target Price at $36.25

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have received an average recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $36.25.

Several analysts recently issued reports on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Finally, Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday, March 5th.

Smith & Nephew SNATS Trading Down 1.0%

Smith & Nephew SNATS stock opened at $33.03 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 12 month low of $23.91 and a 12 month high of $38.79. The stock’s 50 day moving average is $34.46 and its 200-day moving average is $34.83.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be given a $0.482 dividend. This represents a dividend yield of 281.0%. The ex-dividend date is Friday, March 27th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Large investors have recently added to or reduced their stakes in the stock. Equity Investment Corp raised its holdings in Smith & Nephew SNATS by 3.9% in the 4th quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after acquiring an additional 285 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Smith & Nephew SNATS by 13.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 334 shares in the last quarter. Cary Street Partners Financial LLC grew its holdings in shares of Smith & Nephew SNATS by 1.8% during the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after purchasing an additional 365 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Smith & Nephew SNATS by 11.7% in the third quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 401 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Smith & Nephew SNATS by 5.0% in the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock worth $323,000 after purchasing an additional 423 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.